Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) is a biopharmaceutical company that focuses on developing medicines that treat intractable diseases by silencing the genes that cause them. The company is part of a competitive industry with peers like Alnylam Pharmaceuticals, Amicus Therapeutics, ACADIA Pharmaceuticals, and Axsome Therapeutics. These companies are all involved in the development of innovative therapies, making the comparison of their financial metrics crucial for investors.
Arrowhead Pharmaceuticals boasts a Return on Invested Capital (ROIC) of 20.84%, which is significantly higher than its Weighted Average Cost of Capital (WACC) of 9.86%. This results in a ROIC to WACC ratio of 2.11, indicating that the company is efficiently utilizing its capital to generate returns. This efficiency suggests that Arrowhead is well-positioned for potential growth and value creation.
In contrast, Alnylam Pharmaceuticals has a negative ROIC of -10.44%, which is below its WACC of 5.30%. This results in a ROIC to WACC ratio of -1.97, highlighting inefficiencies in capital utilization. Similarly, Amicus Therapeutics also struggles with a negative ROIC of -13.65% against a WACC of 6.20%, resulting in a ROIC to WACC ratio of -2.20. These figures suggest challenges in generating returns above their cost of capital.
ACADIA Pharmaceuticals, however, stands out with a ROIC of 23.32%, which is well above its WACC of 6.74%. This results in a ROIC to WACC ratio of 3.46, indicating strong capital efficiency and growth potential. This makes ACADIA a leader among its peers in terms of capital management and potential for future growth.
Axsome Therapeutics presents a different scenario with a notably negative ROIC of -55.37%, far below its WACC of 5.53%. This results in a ROIC to WACC ratio of -10.02, highlighting substantial inefficiencies in capital utilization. This suggests that Axsome faces significant challenges in generating returns that exceed its cost of capital.
